NDLI: Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes.

Please wait, while we are loading the content...

Intranasal delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin-resistant C57BLK/6-m db/db mice.

Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity.

Cerebellin1 is a novel orexigenic peptide.

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.

Effects of central administration of insulin or l-NMMA on rat skeletal muscle microvascular perfusion.

Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.

Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial.

Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes.

Response to Fritsche et al. (GINGER study).

Year: 2010 Volume: 12 Issue: 9

Year: 2010 Volume: 12 Issue: 8

Year: 2010 Volume: 12 Issue: 7

Year: 2010 Volume: 12 Issue: 6

Year: 2010 Volume: 12 Issue: 5

Year: 2010 Volume: 12 Issue: 4

Year: 2010 Volume: 12 Issue: 3

Year: 2010 Volume: 12 Issue: 2

Year: 2010 Volume: 12 Issue: Supplementary 2

Year: 2010 Volume: 12 Issue: 1

Year: 2010 Volume: 12 Issue: Supplementary 1

Year: 2009 Volume: 11

Year: 2008 Volume: 10

Year: 2007 Volume: 9

Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Swinnen, S. G. Dain, M-P Mauricio, D. DeVries, J. H. Hoekstra, J. B. Holleman, F.
Description	Country affiliation: Netherlands Author Affiliation: Swinnen SG ( Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands.)
Abstract	We compared the combined use of basal insulin, metformin and insulin secretagogues with a combination of basal insulin and metformin in patients with type 2 diabetes starting basal insulin analogue therapy. This analysis was part of a 24-week trial, in which 964 insulin-naive patients with type 2 diabetes inadequately controlled on oral agents (including metformin) were randomized to insulin glargine or detemir. Secretagogues were stopped or maintained at the site-investigators' discretion. During the study, 57.6% of patients continued their secretagogue treatment. Compared with patients stopping secretagogues, those who continued experienced significantly more hypoglycaemia and weight gain. Insulin doses, however, were significantly lower: 0.6 ± 0.4 versus 0.8 ± 0.4 U/kg/day (p < 0.001). The difference between groups in mean HbA1c reduction was not statistically significant. In conclusion, in type 2 diabetic patients starting basal insulin analogue therapy, continuing both metformin and secretagogues results in more hypoglycaemia and weight gain and lower insulin doses than only maintaining metformin.
File Format	HTM / HTML
ISSN	14628902
Issue Number	10
Volume Number	12
e-ISSN	14631326
Journal	Diabetes, Obesity and Metabolism
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2010-10-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Metabolism Discipline Endocrinology Discipline Pharmacology Discipline Diabetology Diabetes Mellitus, Type 2 Drug Therapy Hemoglobin A, Glycosylated Drug Effects Hypoglycemic Agents Administration & Dosage Insulin Metformin Adult Aged Female Humans Analogs & Derivatives Male Middle Aged Sulfonylurea Compounds Treatment Outcome Weight Gain Journal Article Randomized Controlled Trial Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Internal Medicine Endocrinology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine.

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes.

Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.

Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus.

Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).

Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.

Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes.

Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients.

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes.

Similar Documents

Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine.

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes.

Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.

Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus.

Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).

Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.

Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes.

Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients.

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes.